Pani Pier Paolo, Trogu Emanuela, Vacca Rosangela, Amato Laura, Vecchi Simona, Davoli Marina
Social-Health Division, Health District 8 (ASL 8) Cagliari, Cittadella della Salute, padiglione C, via Romagna 16, Cagliari, Sardinia, Italy, 09127.
Cochrane Database Syst Rev. 2010 Jan 20(1):CD007024. doi: 10.1002/14651858.CD007024.pub2.
Cocaine dependence is a disorder for which no pharmacological treatment of proven efficacy exists, advances in the neurobiology could guide future medication development.
To evaluate the efficacy and the acceptability of disulfiram for cocaine dependence.
We searched: PubMed, EMBASE, CINAHL (up to January 2008), the Cochrane Central Register of Controlled Trials (CENTRAL-The Cochrane Library, 1, 2009), reference lists of trials, main electronic sources of ongoing trials, conference proceedings.
Randomised and controlled clinical trials comparing disulfiram alone or associated with psychosocial intervention with no intervention, placebo, or other pharmacological intervention for the treatment of cocaine dependence.
Three reviewers independently assessed trial quality and extracted data.
Seven studies, 492 participants, met the inclusion criteriaDisulfiram versus placebo: no statistically significant results for dropouts but a trend favouring disulfiram, two studies, 87 participants, RR 0.82 (95% CI 0.66 to 1.03). One more study, 107 participants, favouring disulfiram, was excluded from meta-analysis due high heterogeneity, RR 0.34 (95% CI 0.20 to 0.58). For cocaine use, it was not possible to pool together primary studies, results from single studies showed that, one, out of four comparisons, was in favour of disulfiram (number of weeks abstinence, 20 participants, WMD 4.50 (95% CI 2.93 to 6.07).Disulfiram versus naltrexone: no statistically significant results for dropouts but a trend favouring disulfiram, three studies, 131 participants, RR 0.67 (95% CI 0.45 to 1.01). No significant difference for cocaine use was seen in the only study that considered this outcome.Disulfiram versus no pharmacological treatment: for cocaine use: a statistically significant difference in favour of disulfiram, one study, two comparisons, 90 participants: maximum weeks of consecutive abstinence, WMD 2.10 (95% CI 0.69 to 3.51); number of subjects achieving 3 or more weeks of consecutive abstinence, RR 1.88 (95% CI 1.09 to 3.23).
AUTHORS' CONCLUSIONS: There is low evidence, at the present, supporting the clinical use of disulfiram for the treatment of cocaine dependence. Larger randomised investigations are needed investigating relevant outcomes and reporting data to allow comparisons of results between studies. Results from ongoing studies will be added as soon as their results will be available.
可卡因成瘾是一种尚无经证实有效的药物治疗方法的疾病,神经生物学的进展可为未来药物研发提供指导。
评估双硫仑治疗可卡因成瘾的疗效和可接受性。
我们检索了:PubMed、EMBASE、CINAHL(截至2008年1月)、Cochrane对照试验中心注册库(CENTRAL - The Cochrane Library,2009年第1期)、试验的参考文献列表、正在进行试验的主要电子资源、会议论文集。
比较单独使用双硫仑或联合心理社会干预与无干预、安慰剂或其他药物干预治疗可卡因成瘾的随机对照临床试验。
三位评价者独立评估试验质量并提取数据。
七项研究,共492名参与者,符合纳入标准
脱落率无统计学显著差异,但有双硫仑更优的趋势,两项研究,87名参与者,RR 0.82(95%CI 0.66至1.03)。另一项有107名参与者、双硫仑更优的研究因异质性高被排除在荟萃分析之外,RR 0.34(95%CI 0.20至0.58)。对于可卡因使用情况,无法汇总主要研究,单项研究结果显示,四项比较中有一项支持双硫仑(禁欲周数,20名参与者,WMD 4.50(95%CI 2.93至6.07))。
脱落率无统计学显著差异,但有双硫仑更优趋势,三项研究131名参与者,RR 0.67(95%CI 0.45至1.01)。在唯一考虑该结果的研究中,可卡因使用情况无显著差异
对于可卡因使用情况:双硫仑有统计学显著优势,一项研究,两项比较,90名参与者:连续禁欲最长周数WMD 2.10(95%CI 0.69至3.5l);连续禁欲达到3周或更长时间的受试者数量,RR 1.88(95%CI 1.09至3.23)
目前仅有低质量证据支持双硫仑用于治疗可卡因成瘾临床使用。需要开展更大规模的随机研究,调查相关结局并报告数据以便进行研究间结果比较。一旦正在进行的研究结果可用,将尽快补充。